62 件 ・ 関連度順
概要と使いどころ
ESG(環境・社会・ガバナンス)レポート作成支援スキル。GRI、SASB、TCFD、CDP等の国際基準に準拠した サステナビリティレポート作成、マテリアリティ分析、KPI設定、データ収集・開示をサポート。 Use when creating sustainability reports, conducting materiality assessments, setting ESG targets, or preparing disclosures aligned with GRI, SASB, TCFD, CDP, or CSRD standards. Triggers: "ESG report", "sustainability report", "TCFD", "GRI", "SASB", "CDP", "materiality assessment", "carbon footprint".
Decides how to preprocess plasma cfDNA sequencing data so the recoverable signal survives - library-prep-aware fragment expectations (dsDNA vs ssDNA/adaptase prep), UMI/duplex consensus with fgbio (ExtractUmisFromBam, GroupReadsByUmi --strategy paired for duplex, CallMolecularConsensusReads vs CallDuplexConsensusReads, FilterConsensusReads min-reads "total s1 s2"), the align->group->consensus->RE-align ordering, and the cfDNA dedup trap where naive coordinate dedup collapses nucleosome-coincident independent molecules. Covers when single-strand consensus suffices vs when duplex is mandatory, the singleton/sensitivity tax at low input, and reading the insert-size histogram as a pre-analytical QC instrument. Use when processing plasma cfDNA reads before fragmentomics, ctDNA mutation calling, or tumor-fraction estimation.
日本語の概要は準備中です。原文の説明を表示しています。
Decides how to preprocess plasma cfDNA sequencing data so the recoverable signal survives - library-prep-aware fragment expectations (dsDNA vs ssDNA/adaptase prep), UMI/duplex consensus with fgbio (ExtractUmisFromBam, GroupReadsByUmi --strategy paired for duplex, CallMolecularConsensusReads vs CallDuplexConsensusReads, FilterConsensusReads min-reads "total s1 s2"), the align->group->consensus->RE-align ordering, and the cfDNA dedup trap where naive coordinate dedup collapses nucleosome-coincident independent molecules. Covers when single-strand consensus suffices vs when duplex is mandatory, the singleton/sensitivity tax at low input, and reading the insert-size histogram as a pre-analytical QC instrument. Use when processing plasma cfDNA reads before fragmentomics, ctDNA mutation calling, or tumor-fraction estimation.
日本語の概要は準備中です。原文の説明を表示しています。
Preprocesses cell-free DNA sequencing data including adapter trimming, alignment optimized for short fragments, and UMI-aware duplicate removal using fgbio. Applies cfDNA-specific quality thresholds and fragment length filtering. Use when processing plasma cfDNA sequencing data before downstream analysis.
日本語の概要は準備中です。原文の説明を表示しています。
Detects cancer and infers tissue-of-origin from cfDNA methylation by choosing conversion chemistry (bisulfite vs EM-seq vs TAPS vs cfMeDIP), calling read-level methylation haplotypes rather than averaged beta values, and deconvolving a hematopoietic-dominated cfDNA mixture against a methylation atlas via NNLS/quadratic programming. Encodes the GRAIL/CCGA thesis that thousands of tissue-specific markers make methylation outperform sparse mutations for multi-cancer early detection (MCED) and localization, and that single concordantly-methylated fragments give ppm-level sensitivity. Uses MethylDackel for extraction (mbias-then-extract), MEDIPS/QSEA for enrichment data, scipy.optimize.nnls for deconvolution. Use when building an MCED or methylation-MRD assay, picking a conversion chemistry for low-input plasma, or deconvolving tissue-of-origin from cfDNA.
日本語の概要は準備中です。原文の説明を表示しています。
Preprocesses cell-free DNA sequencing data including adapter trimming, alignment optimized for short fragments, and UMI-aware duplicate removal using fgbio. Applies cfDNA-specific quality thresholds and fragment length filtering. Use when processing plasma cfDNA sequencing data before downstream analysis.
日本語の概要は準備中です。原文の説明を表示しています。
Create consistent nn_cfd W&B experiment comparison reports from selected run IDs using wandb and wandb_workspaces. Use this whenever the user asks to report experiment results, create a W&B Report, compare CFD training/eval runs, document baseline-vs-variant outcomes, reproduce the project experiment report template, or publish a leaderboard-style report for milieu/nn_cfd.
日本語の概要は準備中です。原文の説明を表示しています。
"Net-zero transition playbook: GHG inventory (ISO 14064-1, GHG Protocol Scope 1/2/3), science-based targets (SBTi), TCFD and ISSB S1/S2 climate disclosure, Taiwan carbon fee, decarbonization roadmap, internal carbon pricing, supply-chain carbon, product carbon footprint, green electricity and T-REC. Use for corporate decarbonization roadmap, carbon inventory, carbon-fee response, TCFD/ISSB reporting, supply-chain decarbonization, or responding to international customers (Apple, RE100). Triggers: 『碳盤查』『SBTi』『碳費』『TCFD』『淨零路徑』『範疇 3』『綠電』『CBAM』『ISO 14064』『ISSB』『T-REC』. For Taiwan EMBA ESG/sustainability/operations/strategy/finance cases. Focuses on Taiwan listed-company and supply-chain practice; sustainability strategy theory: use Asgard `grad-sustainability`; ERM 框架整合氣候風險: use `biz-erm`; 董事會 ESG 委員會結構設計: use `biz-corporate-governance`; 併購 ESG 盡職調查: use `fin-m-and-a`.".
日本語の概要は準備中です。原文の説明を表示しています。
Extracts cfDNA fragmentomics features (DELFI genome-wide short/long ratios, WPS nucleosome positioning, Griffin GC-corrected accessibility profiles, end-motifs/MDS, OCF) for cancer detection and tissue-of-origin from plasma WGS. Centers on the nuclease-footprint reframe (every feature re-reads one nucleosome object), the mandatory GC correction, and the cross-protocol non-comparability that breaks naive classifiers. Runs FinaleToolkit (real CLI/Python, MIT) and the Griffin Snakemake pipeline; DELFI is a method, not a package. Use when deriving fragment-based signal from cfDNA, choosing a feature family for detection vs subtyping, or diagnosing why a fragmentomic model failed validation.
日本語の概要は準備中です。原文の説明を表示しています。
Estimates tumor fraction (the genome-wide proportion of cfDNA molecules that are tumor-derived, the cfDNA analogue of bulk-tumor purity) from shallow whole-genome sequencing with ichorCNA, an HMM over 1 Mb bins that jointly EM-estimates tumor fraction, ploidy, and subclonal prevalence over a normal/ploidy grid. Encodes the load-bearing reframes: tumor fraction is the quantity that travels across assays and is NOT mutation VAF (clonal-het VAF approximately TF/2), CNA-based estimation has a hard ~3 percent limit-of-detection floor, and near-diploid or copy-neutral-LOH genomes return a falsely low value. Selects the estimator by data type (sWGS to ichorCNA, deep panel to max-VAF, methylation to deconvolution, sub-3 percent to fragmentomics or methylation). Use when quantifying tumor burden from a liquid biopsy, picking a tumor-fraction estimator for a given assay, or reconciling a TF estimate against a panel VAF.
日本語の概要は準備中です。原文の説明を表示しています。
Assess competitor defensibility and define our own moat strategy during PRD v0.3 Commercial Model. Triggers on requests to analyze competitor moats, define our defensibility, assess switching costs, identify vulnerabilities, find wedge opportunities, or when user asks "what's our moat?", "how defensible are they?", "where can we compete?", "switching costs?", "defensibility", "who to target". Consumes Competitive Landscape (v0.2) CFD- entries. Outputs CFD- entries for competitor moats and BR- entries for targeting rules and our defensibility strategy.
日本語の概要は準備中です。原文の説明を表示しています。
Monitor federal grant opportunities across Grants.gov (Simpler.grants.gov is the modern UX), SAM.gov assistance listings (the post-CFDA replacement that preserves CFDA program numbers), and direct agency portals — NIH RePORTER + NIH Guide, NSF Funding, DOE OSTI, USDA NIFA, EPA Grants.
日本語の概要は準備中です。原文の説明を表示しています。
Extracts cfDNA fragmentomics features (DELFI genome-wide short/long ratios, WPS nucleosome positioning, Griffin GC-corrected accessibility profiles, end-motifs/MDS, OCF) for cancer detection and tissue-of-origin from plasma WGS. Centers on the nuclease-footprint reframe (every feature re-reads one nucleosome object), the mandatory GC correction, and the cross-protocol non-comparability that breaks naive classifiers. Runs FinaleToolkit (real CLI/Python, MIT) and the Griffin Snakemake pipeline; DELFI is a method, not a package. Use when deriving fragment-based signal from cfDNA, choosing a feature family for detection vs subtyping, or diagnosing why a fragmentomic model failed validation.
日本語の概要は準備中です。原文の説明を表示しています。
Expert-level aerodynamics covering subsonic and supersonic flow, lift and drag, airfoil theory, boundary layers, compressible flow, and CFD methods.
日本語の概要は準備中です。原文の説明を表示しています。
Extract structured fields from cfdi carta porte documents.
日本語の概要は準備中です。原文の説明を表示しています。
Extract structured fields from cfdi invoice documents.
日本語の概要は準備中です。原文の説明を表示しています。
Extract structured fields from cfdi nomina documents.
日本語の概要は準備中です。原文の説明を表示しています。
Official NVIDIA-authored guidance for navigating PhysicsNeMo — pick the model, datapipe, or example for a SciML/AI4Science task (surrogates, forecasting, downscaling, physics-informed, inverse, generative). Points at existing files via live repo search; never writes code. Do NOT use for installation or environment setup, training-loop or other code authoring/scaffolding, contributor/CI/packaging questions, repo-specific questions in physicsnemo-sym/-cfd/-curator, or general (non-physics) ML/PyTorch.
日本語の概要は準備中です。原文の説明を表示しています。
Analyzes cfDNA methylation patterns for cancer detection using cfMeDIP-seq or bisulfite sequencing with MethylDackel. Identifies cancer-specific methylation signatures and performs tissue-of-origin deconvolution. Use when using methylation biomarkers for early cancer detection or minimal residual disease.
日本語の概要は準備中です。原文の説明を表示しています。
Analyzes cfDNA fragment size distributions and fragmentomics features using FinaleToolkit or Griffin. Extracts nucleosome positioning patterns, fragment ratios, and DELFI-style fragmentation profiles for cancer detection. Use when leveraging fragment patterns for tumor detection or tissue-of-origin analysis.
日本語の概要は準備中です。原文の説明を表示しています。
Predict CRISPR off-target sites using Cas-OFFinder and CFD scoring algorithms. Identify potential unintended cleavage sites genome-wide and assess guide specificity. Use when evaluating guide RNA specificity or selecting guides with minimal off-target risk.
日本語の概要は準備中です。原文の説明を表示しています。
Assess physical and transition climate risk for a site, product, or portfolio with scenario-based structure. Use when asked to run a climate risk assessment, evaluate physical or transition risk, prepare TCFD/ESRS-style climate risk analysis, or assess how climate scenarios affect an asset or business. Produces a hazard-exposure-vulnerability matrix across 2030/2040/2050 horizons and labelled scenarios, with financial-impact ranges, confidence levels, and adaptation options.
日本語の概要は準備中です。原文の説明を表示しています。
Detects somatic mutations in circulating tumor DNA, treating low-VAF detection as a signal-versus-noise problem set by error suppression and molecules sampled, not by the choice of caller. Distinguishes de novo CALLING (scanning a panel for unknown variants, bounded by per-locus error and multiple testing) from tumor-informed DETECTION (tracking a pre-specified variant set, where panel integration reaches single-ppm). Covers VarDict and Mutect2 for de novo calling, UMI-aware callers, and a pysam-based known-variant VAF tracker, with matched-WBC subtraction as the mandatory defense against clonal hematopoiesis (the dominant false positive). Use when calling or tracking tumor mutations from plasma cfDNA, setting a VAF threshold, or deciding whether a low-VAF call is tumor versus CHIP.
日本語の概要は準備中です。原文の説明を表示しています。
Nominates and assesses CRISPR off-target sites genome-wide. Enumerates candidate sites by mismatch and bulge tolerance with Cas-OFFinder/CRISPRitz, ranks them with the published CFD score (SpCas9-only, relative ranker) or MIT/CRISTA/energy models, runs variant-aware screening against gnomAD/individual genomes (CRISPRme), and frames the empirical genome-wide discovery assays (GUIDE-seq, CIRCLE-seq, CHANGE-seq, DISCOVER-seq, Digenome-seq) and high-fidelity nuclease choice (HiFi Cas9, Sniper-Cas9, eSpCas9, SpCas9-HF1). Use when assessing guide RNA specificity, choosing among candidate guides, screening a therapeutic guide against population variation, or planning empirical off-target validation. Distinguishes predicted vs detected vs validated. On-target activity scoring and deaminase (Cas-independent) base/prime-editor off-targets are separate skills.
日本語の概要は準備中です。原文の説明を表示しています。